RecruitingNCT05060783

Renal Cancer Detection With Liquid Biopsy

Sponsor

Zealand University Hospital

Enrollment

200 participants

Start Date

Jul 1, 2021

Study Type

OBSERVATIONAL

Conditions

Renal Cancer Oncocytoma

Summary

Glycosaminoglycans (GAGs) were significantly altered in localized as well advanced RCC compared to healthy samples. In addition, GAG scores correlated with progression-free survival and overall survival (OS) in a prospective cohort of patients with metastatic ccRCC and localized RCC. However, it is still unknown whether alterations in plasma and urine GAGs are exquisitely specific to RCC or are shared by other benign lesions in the kidney, such as angiomyolipomas, oncocytomas, or PEComa.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether a liquid biopsy — a simple blood test that looks for cancer DNA — can reliably detect clear cell renal (kidney) cancer. This could one day help diagnose kidney cancer without invasive biopsies. **You may be eligible if...** - You have been evaluated by CT scan with suspicion of a kidney tumor but scans do not show cancer, OR - You have a confirmed clear cell kidney cancer (ccRCC) or a benign kidney tumor called oncocytoma verified by biopsy or surgery - You can provide informed consent **You may NOT be eligible if...** - You have a non-clear cell kidney cancer subtype - You have kidney cancer with sarcomatoid features - You are on blood-thinning medications (heparin) for an active clot Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.